Outpatient vancomycin therapy: Acute kidney injury in individualized AUC-based goal trough ranges versus traditional trough dosing

• Published in: Journal of the American Pharmacists Association Vol. 62; no. 3; p. 706
• Main Authors: Rees, Marissa R, Carr, Dustin R, Trienski, Tamara, Buchanan, Carley, White, Kara, Bremmer, Derek N
• Format: Journal Article
• Language: English
• Published: United States 01.05.2022
• Subjects: Acute Kidney Injury - chemically induced; Acute Kidney Injury - epidemiology; Anti-Bacterial Agents - therapeutic use; Area Under Curve; Female; Goals; Humans; Male; Microbial Sensitivity Tests; Outpatients; Retrospective Studies; Vancomycin - adverse effects
• ISSN: 1544-3450
• DOI: 10.1016/j.japh.2021.11.031

Recent changes to vancomycin guidelines recommend area under the curve concentration (AUC) monitoring in most patients, owing to similar effectiveness and reduced rates of acute kidney injury (AKI). The purpose of this study was to assess the incidence of AKI in patients receiving vancomycin dosed by AUC-based goal troughs and vancomycin dosed by traditional trough goals (15-20 mcg/mL) in the outpatient setting. Patients were included if they received vancomycin outpatient for at least 1 week. The primary objective was comparing the incidence of AKI in patients receiving vancomycin as an outpatient with trough goals derived from patient-specific AUC calculations determined as an inpatient with that of patients receiving vancomycin by traditional goal troughs. Secondary objectives included assessing the rate of treatment failure, AUC estimated trough range, and number of regimen changes required. There were 65 patients in the traditional trough dosing group and 53 patients in the AUC trough dosing group. The incidence of AKI was lower in the AUC trough group (5.7% vs. 23.1%; P = 0.01). There were no differences in the incidence of treatment failure. The median AUC estimated trough range was 11.4-17.1 mcg/mL. There were statistically significant less average regimen changes required in the AUC dosing group (1.13 vs. 1.64; P = 0.006). There was a statistically significant lower incidence of AKI in patients receiving vancomycin dosed by individualized AUC-based trough ranges compared with that of patients receiving traditional trough dosing. Developing a process for individualized AUC-based trough ranges can facilitate a convenient monitoring method to use the benefits of vancomycin AUC dosing as an outpatient.